<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <atom:link rel="self" type="application/rss+xml" href="https://escholarship.org/uc/nobel_h2012_yamanaka/rss"/>
    <ttl>720</ttl>
    <title>Recent nobel_h2012_yamanaka items</title>
    <link>https://escholarship.org/uc/nobel_h2012_yamanaka/rss</link>
    <description>Recent eScholarship items from Shinya Yamanaka, UCSF (Nobel Prize in Physiology or Medicine, 2012)</description>
    <pubDate>Sun, 22 Nov 2026 19:33:31 +0000</pubDate>
    <item>
      <title>Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies</title>
      <link>https://escholarship.org/uc/item/8421m2j5</link>
      <description>Long-QT syndrome, a frequently fatal inherited arrhythmia syndrome caused by genetic variants (congenital) or drugs (acquired), affects 1 in 2000 people worldwide. Its sentinel event is often sudden cardiac death, which makes preclinical diagnosis by genetic testing potentially life-saving. Unfortunately, clinical experience with genetic testing has shown that it is difficult to correctly identify genetic variants as disease causing. These current deficiencies in accurately assigning pathogenicity led to the discovery of increasing numbers of rare variants classified as variant of uncertain significance. To overcome these challenges, new technologies such as clustered regularly interspaced short palindromic repeats (CRISPR) genome editing can be combined with human induced pluripotent stem cell-derived cardiomyocytes to provide a new approach to decipher pathogenicity of variants of uncertain significance and to better predict arrhythmia risk. To that end, the overarching goal...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8421m2j5</guid>
      <pubDate>Wed, 24 Jan 2024 00:00:00 +0000</pubDate>
      <author>
        <name>Wu, Joseph C</name>
      </author>
      <author>
        <name>Garg, Priyanka</name>
      </author>
      <author>
        <name>Yoshida, Yoshinori</name>
      </author>
      <author>
        <name>Yamanaka, Shinya</name>
      </author>
      <author>
        <name>Gepstein, Lior</name>
      </author>
      <author>
        <name>Hulot, Jean-Sébastien</name>
      </author>
      <author>
        <name>Knollmann, Björn C</name>
      </author>
      <author>
        <name>Schwartz, Peter J</name>
      </author>
    </item>
    <item>
      <title>MYC Releases Early Reprogrammed Human Cells from Proliferation Pause via Retinoblastoma Protein Inhibition</title>
      <link>https://escholarship.org/uc/item/1xz128gm</link>
      <description>Here, we report that MYC rescues early human cells&amp;nbsp;undergoing reprogramming from a proliferation pause induced by OCT3/4, SOX2, and KLF4 (OSK). We identified ESRG as a marker of early reprogramming cells that is expressed as early as day 3 after OSK induction. On day 4, ESRG positive (+) cells converted to a TRA-1-60 (+) intermediate state. These early ESRG (+) or TRA-1-60 (+) cells showed a proliferation pause due to increased p16INK4A and p21 and decreased endogenous MYC caused by OSK. Exogenous MYC did not enhance the appearance of initial reprogramming cells but instead reactivated their proliferation and improved reprogramming efficiency. MYC increased expression of LIN41, which potently suppressed p21 post-transcriptionally. MYC suppressed p16 INK4A. These changes inactivated retinoblastoma protein (RB) and reactivated proliferation. The RB-regulated proliferation pause does not occur in immortalized fibroblasts, leading to high reprogramming efficiency even without...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1xz128gm</guid>
      <pubDate>Fri, 19 May 2023 00:00:00 +0000</pubDate>
      <author>
        <name>Rand, Tim A</name>
      </author>
      <author>
        <name>Sutou, Kenta</name>
      </author>
      <author>
        <name>Tanabe, Koji</name>
      </author>
      <author>
        <name>Jeong, Daeun</name>
      </author>
      <author>
        <name>Nomura, Masaki</name>
      </author>
      <author>
        <name>Kitaoka, Fumiyo</name>
      </author>
      <author>
        <name>Tomoda, Emi</name>
      </author>
      <author>
        <name>Narita, Megumi</name>
      </author>
      <author>
        <name>Nakamura, Michiko</name>
      </author>
      <author>
        <name>Nakamura, Masahiro</name>
      </author>
      <author>
        <name>Watanabe, Akira</name>
      </author>
      <author>
        <name>Rulifson, Eric</name>
      </author>
      <author>
        <name>Yamanaka, Shinya</name>
      </author>
      <author>
        <name>Takahashi, Kazutoshi</name>
      </author>
    </item>
    <item>
      <title>Structure-based discovery of NANOG variant with enhanced properties to promote self-renewal and reprogramming of pluripotent stem cells</title>
      <link>https://escholarship.org/uc/item/95v8v6mr</link>
      <description>NANOG (from Irish mythology Tír na nÓg) transcription factor plays a central role in maintaining pluripotency, cooperating with OCT4 (also known as POU5F1 or OCT3/4), SOX2, and other pluripotency factors. Although the physiological roles of the NANOG protein have been extensively explored, biochemical and biophysical properties in relation to its structural analysis are poorly understood. Here we determined the crystal structure of the human NANOG homeodomain (hNANOG HD) bound to an OCT4 promoter DNA, which revealed amino acid residues involved in DNA recognition that are likely to be functionally important. We generated a series of hNANOG HD alanine substitution mutants based on the protein-DNA interaction and evolutionary conservation and determined their biological activities. Some mutant proteins were less stable, resulting in loss or decreased affinity for DNA binding. Overexpression of the orthologous mouse NANOG (mNANOG) mutants failed to maintain self-renewal of mouse...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/95v8v6mr</guid>
      <pubDate>Sun, 16 Apr 2023 00:00:00 +0000</pubDate>
      <author>
        <name>Hayashi, Y</name>
      </author>
      <author>
        <name>Caboni, L</name>
      </author>
      <author>
        <name>Das, D</name>
      </author>
      <author>
        <name>Yumoto, F</name>
      </author>
      <author>
        <name>Clayton, T</name>
      </author>
      <author>
        <name>Deller, MC</name>
      </author>
      <author>
        <name>Nguyen, P</name>
      </author>
      <author>
        <name>Farr, CL</name>
      </author>
      <author>
        <name>Chiu, HJ</name>
      </author>
      <author>
        <name>Miller, MD</name>
      </author>
      <author>
        <name>Elsliger, MA</name>
      </author>
      <author>
        <name>Deacon, AM</name>
      </author>
      <author>
        <name>Godzik, A</name>
      </author>
      <author>
        <name>Lesley, SA</name>
      </author>
      <author>
        <name>Tomodaa, K</name>
      </author>
      <author>
        <name>Conklin, BR</name>
        <uri>https://orcid.org/0000-0003-1463-6061</uri>
      </author>
      <author>
        <name>Wilson, IA</name>
      </author>
      <author>
        <name>Yamanaka, S</name>
      </author>
      <author>
        <name>Fletterick, RJ</name>
      </author>
    </item>
    <item>
      <title>Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells</title>
      <link>https://escholarship.org/uc/item/96c487b6</link>
      <description>The International Stem Cell Initiative compared several commonly used approaches to assess human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) formation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we report that EB assays, analyzed after differentiation under neutral conditions and under conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by histologic examination and by TeratoScore, which estimates differential gene expression in each tumor, not only measures differentiation but also allows insight into a PSC's malignant potential. Each of the assays can be used to predict pluripotent differentiation potential but, at this stage of assay development, only the teratoma assay provides an assessment...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/96c487b6</guid>
      <pubDate>Fri, 22 Jul 2022 00:00:00 +0000</pubDate>
      <author>
        <name>Allison, TF</name>
      </author>
      <author>
        <name>Andrews, PW</name>
        <uri>https://orcid.org/0000-0001-7215-4410</uri>
      </author>
      <author>
        <name>Avior, Y</name>
      </author>
      <author>
        <name>Barbaric, I</name>
      </author>
      <author>
        <name>Benvenisty, N</name>
      </author>
      <author>
        <name>Bock, C</name>
        <uri>https://orcid.org/0000-0001-6091-3088</uri>
      </author>
      <author>
        <name>Brehm, J</name>
      </author>
      <author>
        <name>Brüstle, O</name>
      </author>
      <author>
        <name>Damjanov, I</name>
        <uri>https://orcid.org/0000-0002-1394-6052</uri>
      </author>
      <author>
        <name>Elefanty, A</name>
      </author>
      <author>
        <name>Felkner, D</name>
      </author>
      <author>
        <name>Gokhale, PJ</name>
      </author>
      <author>
        <name>Halbritter, F</name>
        <uri>https://orcid.org/0000-0003-2452-4784</uri>
      </author>
      <author>
        <name>Healy, LE</name>
      </author>
      <author>
        <name>Hu, TX</name>
        <uri>https://orcid.org/0000-0003-0446-3144</uri>
      </author>
      <author>
        <name>Knowles, BB</name>
      </author>
      <author>
        <name>Loring, JF</name>
        <uri>https://orcid.org/0000-0001-6226-9767</uri>
      </author>
      <author>
        <name>Ludwig, TE</name>
      </author>
      <author>
        <name>Mayberry, R</name>
      </author>
      <author>
        <name>Micallef, S</name>
      </author>
      <author>
        <name>Mohamed, JS</name>
      </author>
      <author>
        <name>Müller, FJ</name>
        <uri>https://orcid.org/0000-0001-9478-8430</uri>
      </author>
      <author>
        <name>Mummery, CL</name>
      </author>
      <author>
        <name>Nakatsuji, N</name>
      </author>
      <author>
        <name>Ng, ES</name>
      </author>
      <author>
        <name>Oh, SKW</name>
      </author>
      <author>
        <name>O'Shea, O</name>
      </author>
      <author>
        <name>Pera, MF</name>
      </author>
      <author>
        <name>Reubinoff, B</name>
      </author>
      <author>
        <name>Robson, P</name>
        <uri>https://orcid.org/0000-0002-0191-3958</uri>
      </author>
      <author>
        <name>Rossant, J</name>
        <uri>https://orcid.org/0000-0002-3731-5466</uri>
      </author>
      <author>
        <name>Schuldt, BM</name>
      </author>
      <author>
        <name>Solter, D</name>
      </author>
      <author>
        <name>Sourris, K</name>
      </author>
      <author>
        <name>Stacey, G</name>
      </author>
      <author>
        <name>Stanley, EG</name>
      </author>
      <author>
        <name>Suemori, H</name>
      </author>
      <author>
        <name>Takahashi, K</name>
      </author>
      <author>
        <name>Yamanaka, S</name>
      </author>
    </item>
    <item>
      <title>Enhanced engraftment, proliferation and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes</title>
      <link>https://escholarship.org/uc/item/7br5z2dd</link>
      <description>Human pluripotent stem cell-derived cardiomyocytes (CMs) are a promising tool for cardiac cell therapy. Although transplantation of induced pluripotent stem cell (iPSC)-derived CMs have been reported in several animal models, the treatment effect was limited, probably due to poor optimization of the injected cells. To optimize graft cells for cardiac reconstruction, we compared the engraftment efficiency of intramyocardially-injected undifferentiated-iPSCs, day4 mesodermal cells and day8, day20 and day30 purified iPSC-CMs after initial differentiation by tracing the engraftment ratio (ER) using in vivo bioluminescence imaging. This analysis revealed the ER of day20 CMs was significantly higher compared to other cells. Transplantation of day20 CMs into the infarcted hearts of immunodeficient mice showed good engraftment and echocardiography showed significant functional improvement by cell therapy. Moreover, the imaging signal and ratio of Ki67-positive CMs at 3 months post injection...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7br5z2dd</guid>
      <pubDate>Fri, 22 Jul 2022 00:00:00 +0000</pubDate>
      <author>
        <name>Funakoshi, Shunsuke</name>
      </author>
      <author>
        <name>Miki, Kenji</name>
      </author>
      <author>
        <name>Takaki, Tadashi</name>
      </author>
      <author>
        <name>Okubo, Chikako</name>
      </author>
      <author>
        <name>Hatani, Takeshi</name>
      </author>
      <author>
        <name>Chonabayashi, Kazuhisa</name>
      </author>
      <author>
        <name>Nishikawa, Misato</name>
      </author>
      <author>
        <name>Takei, Ikue</name>
      </author>
      <author>
        <name>Oishi, Akiko</name>
      </author>
      <author>
        <name>Narita, Megumi</name>
      </author>
      <author>
        <name>Hoshijima, Masahiko</name>
      </author>
      <author>
        <name>Kimura, Takeshi</name>
      </author>
      <author>
        <name>Yamanaka, Shinya</name>
      </author>
      <author>
        <name>Yoshida, Yoshinori</name>
      </author>
    </item>
  </channel>
</rss>
